Még nem toboroz
Perceived Autonomy in Performing Intravenous Injections for Patients With Severe or Moderate Hemophilia A Receiving Emicizumab
NCT07946120· University Hospital, Caen· Forrás
Contact: Stéphane VANDERBECKEN, Medical Doctor
Toboroz
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· 3. fázis· UNICANCER· Forrás
Toboroz
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
NCT06918002· 3. fázis· Intergroupe Francophone du Myelome· Forrás
Toboroz
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
NCT06625970· 3. fázis· UNICANCER· Forrás
Toboroz
Short versus long antiplatelet therapy after TAVI
2023-508208-40-00· 2/3. fázis· Centre Hospitalier Universitaire De Caen Normandie· Forrás
Toboroz
Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms
2024-515362-13-00· 2/3. fázis· Centre Hospitalier Regional Et Universitaire De Brest· Forrás
Meghívásos bevonás
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
NCT06475742· 3. fázis· Viatris Innovation GmbH· Forrás
Toboroz
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00· 3. fázis· Institut Gustave Roussy· Forrás
Fut, nem toboroz
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
NCT06109649· 3. fázis· Clinuvel, Inc.· Forrás
Fut, nem toboroz
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
NCT05219318· 3. fázis· University Hospital, Bordeaux· Forrás
Fut, nem toboroz
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500· 3. fázis· Viatris Innovation GmbH· Forrás
Toboroz
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
NCT05476939· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Fut, nem toboroz
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· 2/3. fázis· Sanofi· Forrás
Fut, nem toboroz
MInimal Residual Disease Adapted Strategy
NCT04934475· 3. fázis· Intergroupe Francophone du Myelome· Forrás
Toboroz
Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome
NCT04681417· 2/3. fázis· Institut Curie· Forrás
Toboroz
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· 1/2. fázis· University of Birmingham· Forrás
Toboroz
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576· 3. fázis· Mats Heyman· Forrás
Toboroz
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
2022-501454-11-00· 3. fázis· GPOH gGmbH· Forrás
Toboroz
SIOP RANDOMET 2017
2023-508926-91-00· 3. fázis· GPOH gGmbH· Forrás
Toboroz
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Toboroz
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
NCT04793919· 2. fázis· Associazione Italiana Ematologia Oncologia Pediatrica· Forrás
Fut, nem toboroz
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
NCT03977194· 3. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Fut, nem toboroz
Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (Cohort 2) - NIVO ALCL
2024-516807-17-00· 2. fázis· Institut Gustave Roussy· Forrás
Fut, nem toboroz
Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients
NCT03643133· 2. fázis· UNICANCER· Forrás
Fut, nem toboroz
Paediatric Hepatic International Tumour Trial
NCT03017326· 3. fázis· University of Birmingham· Forrás
Fut, nem toboroz
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
NCT02215265· 3. fázis· Lisette Nixon· Forrás
Toboroz
SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma
NCT02265770· 2/3. fázis· Centre Leon Berard· Forrás
Fut, nem toboroz
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
NCT02066220· 2/3. fázis· Universitätsklinikum Hamburg-Eppendorf· Forrás